Fund Holdings — Patient Square Capital LP

Total Portfolio Value:
$241.72M
Total Bought:
$29.40M
Total Sold:
$17.23M
Net Transaction:
+$12.17M
Securities
▲▼
SharesValue
Q4 2024
▲▼
Q1 2025
▲▼
Change
▲▼
Q4 2024
▲▼
Q1 2025
▲▼
Weight (%)
▲▼
Change
▲▼
Roivant Sciences Ltd.SHS(ROIV)12,480,00012,480,0000$147.64M$125.92M52.09%-$21.72M
Insmed Incorporated(INSM)307,167330,250+23,083$21.21M$25.19M10.42%+$3.99M
Liquidia Corporation(LQDA)1,860,3711,522,452-337,919$21.88M$22.46M9.29%+$578.2K
EyePoint, Inc.(EYPT)1,410,3311,481,977+71,646$10.51M$8.03M3.32%-$2.47M
Ocular Therapeutix, Inc.(OCUL)470,919920,199+449,280$4.02M$6.75M2.79%+$2.72M
Cullinan Therapeutics, Inc.(CGEM)878,897878,8970$10.70M$6.65M2.75%-$4.05M
Nurix Therapeutics, Inc.(NRIX)446,296447,296+1,000$8.41M$5.31M2.20%-$3.09M
Mirum Pharmaceuticals, Inc.(MIRM)64,900116,362+51,462$2.68M$5.24M2.17%+$2.56M
Enliven Therapeutics, Inc.224,038253,838+29,800$5.04M$5.00M2.07%-$45.3K
Scholar Rock Holding Corporation(SRRK)32,000154,000+122,000$1.38M$4.95M2.05%+$3.57M
Disc Medicine, Inc.(IRON)56,40083,000+26,600$3.58M$4.12M1.70%+$544.4K
Agios Pharmaceuticals, Inc.(AGIO)121,732139,732+18,000$4.00M$4.09M1.69%+$94.0K
Kymera Therapeutics, Inc.(KYMR)0142,201+142,201$0$3.89M1.61%+$3.89M
Pharvaris N. V.
COM
207,603245,496+37,893$3.98M$3.85M1.59%-$125.5K
Allogene Therapeutics, Inc.1,489,9092,368,186+878,277$3.17M$3.46M1.43%+$284.0K
Blueprint Medicines Corporation038,500+38,500$0$3.41M1.41%+$3.41M
Intellia Therapeutics, Inc.(NTLA)215,981232,781+16,800$2.52M$1.66M0.68%-$863.3K
Soleno Therapeutics, Inc.018,600+18,600$0$1.33M0.55%+$1.33M
Yarrow Bioscience Inc(YARW)0257,033+257,033$0$406.1K0.17%+$406.1K
Astria Therapeutics Inc105,0570-105,057$939.2K$0—-$939.2K
Arvinas, Inc.(ARVN)86,6270-86,627$1.66M$0—-$1.66M
Geron Corporation(GERN)1,321,2680-1,321,268$4.68M$0—-$4.68M
Intra-Cellular Therapies Inc.71,9900-71,990$6.01M$0—-$6.01M
Springworks Therapeutics, Inc.93,1370-93,137$3.37M$0—-$3.37M
Page 1 of 1
Patient Square Capital LP — 13F Holdings — Q1 2025 | TickerTrail